

## Chronic kidney disease after liver transplantation

Leithead, Joanna A.; Ferguson, James W.

DOI:

[10.1016/j.jhep.2014.08.054](https://doi.org/10.1016/j.jhep.2014.08.054)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Leithead, JA & Ferguson, JW 2015, 'Chronic kidney disease after liver transplantation', *Journal of Hepatology*, vol. 62, no. 1, pp. 243-244. <https://doi.org/10.1016/j.jhep.2014.08.054>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

NOTICE: this is the author's version of a work that was accepted for publication. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Leithead, J.A., Ferguson, J.W., Chronic kidney disease after liver transplantation, *Journal of Hepatology* (2014), doi: <http://dx.doi.org/10.1016/j.jhep.2014.08.054>

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Accepted Manuscript

Letter to the Editor

Chronic kidney disease after liver transplantation

Joanna A. Leithead, James W. Ferguson

PII: S0168-8278(14)00713-2

DOI: <http://dx.doi.org/10.1016/j.jhep.2014.08.054>

Reference: JHEPAT 5358


To appear in: *Journal of Hepatology*

Received Date: 22 July 2014

Accepted Date: 19 August 2014

Please cite this article as: Leithead, J.A., Ferguson, J.W., Chronic kidney disease after liver transplantation, *Journal of Hepatology* (2014), doi: <http://dx.doi.org/10.1016/j.jhep.2014.08.054>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Chronic kidney disease after liver transplantation**

<sup>1,2</sup>Joanna A Leithead, <sup>1</sup>James W Ferguson

<sup>1</sup>Liver Unit, Queen Elizabeth Hospital, Birmingham, UK

<sup>2</sup>NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, UK

**Key words:** Liver transplantation, chronic kidney disease, acute kidney injury, MELD, mortality

**Word count:** 713 (including references)

**Number of tables:** 0

**Number of figures:** 0

**Corresponding author:**

Joanna Agnes Leithead, Clinical Lecturer in Hepatology  
Centre for Liver Research, NIHR Biomedical Research Unit  
Institute of Biomedical Research (5<sup>th</sup> floor)  
University of Birmingham  
Edgbaston  
Birmingham, UK, B15 2TT  
Tel: 0121 415 8700 Fax: 0121 415 8701  
j.a.leithead@bham.ac.uk

**Disclosure:** The authors of this manuscript have no conflict of interest to disclose as described by the Journal of Hepatology.

**Financial support:** None

To the Editor:

We read with interest the report by Allen et al in a recent issue of Journal of Hepatology (1). The authors are to be congratulated on highlighting the important problem of chronic kidney disease (CKD) in liver transplant recipients. Instead of concentrating on severe CKD (KDIGO stages 4 to 5) as in most previous literature, their study additionally described the incidence of lesser degrees of renal injury (KDIGO stage 3) and had the benefit of iothalamate-measured glomerular filtration rate (GFR). They found that few patients maintained 'normal' renal function long-term after transplantation, with two thirds developing CKD by 10 years. The majority of patients had stage 3 disease. However, echoing observations in the nontransplant setting, this moderate CKD (GFR <60 ml/min/1.73m<sup>2</sup>) was clinically relevant having implications for survival (2,3).

There are several points worthy of comment. Firstly, although there was clearly a progressive deterioration in renal function with time after transplant, the greatest loss occurred within the first year. The authors speculated that this reflects nephrotoxic immunosuppressive drugs. Little mention was made of the role of peri-operative acute kidney injury (AKI). In our unit, despite optimised pre-transplant renal function and less calcineurin inhibitor exposure in recent years, patients are experiencing more GFR loss from baseline to 1-year (4). This is in the context of a rise in the incidence of AKI that has occurred in parallel with a marked rise in the use of higher risk grafts (4). We have hypothesised that graft injury may play a critical role in the pathogenesis of AKI in this setting. It is well recognised that AKI can cause permanent structural damage, with progressive tubulo-interstitial fibrosis and long-term repercussions for

renal function (5). Therefore, we suggest that in addition to renal sparing immunosuppression, future strategies to prevent CKD may include therapies that minimise the renal hit at time of transplantation.

Secondly, the apparent lack of era effect on the frequency of CKD is interesting. United States registry data has shown that the introduction of MELD has been accompanied by an increased likelihood of end-stage kidney disease, which has been attributed to greater pre-operative renal dysfunction (6). Nevertheless, given that the adjusted hazard ratio for renal failure only rose by 15% after MELD implementation, one might not anticipate a demonstrable difference in this comparatively small study. Without detailed information regarding additional recipient and donor factors it is difficult to draw any real conclusions regarding the evolving incidence of CKD. Readers should not be falsely reassured by this data, especially in the face of an escalating use of higher risk grafts.

Finally, a major conclusion of the study by Allen et al was the limited reliability of creatinine-based GFR estimation in predicting mortality in these patients, and that preventative and expectant management based on early recognition of renal dysfunction may require actual measurement of GFR. We argue that measured GFR is time consuming, costly and not an applicable test for most transplant centres when repeated tests are necessary. Although a useful research tool, a single absolute measure of renal function in an individual patient is less relevant than delta estimated GFR for modifying clinical care.

**References**

1. Allen A, Kim WR, Therneau TM, Larson JJ, Heimbach JK, Rule AD. Chronic kidney disease and associated mortality after liver transplantation – A time-dependent analysis using measured glomerular filtration rate. *J Hepatol* 2014; Epub ahead of print.
2. Weiner DE, Tighiouart H, Amin MG, Stark MG, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol* 2004;15:1307-1315.
3. Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of non cardiovascular mortality. *J Am Soc Nephrol* 2005;16(12):3728-35.
4. Leithead JA, Rajoriya N, Gunson BK, Muiesan P, Ferguson JW. The evolving use of higher risk grafts is associated with an increased incidence of acute kidney injury after liver transplantation. *J Hepatol* 2014;60(6):1180-6.
5. Basile SP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. *Am J Physiol Renal Physiol* 2001;281(5):F887-899.
6. Sharma P, Schaubel DE, Guidinger MK, Goodrich NP, Ojo AO, Merion RM. Impact of MELD-based allocation on end-stage renal disease after liver transplantation. *Am J Transplant* 2011;11:2372-2378.